Announcements Trials
Browse Landscape

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 11Observational 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 2Lymphoma, Follicular 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Observational × ibritumomab tiuxetan × Clear all
NCT01448928 2021-10-01

ZEVALIN-DUI

Spectrum Pharmaceuticals, Inc

Completed
400 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT01479387 2011-11-24

ZEVALIN-SDUI

Bayer

Completed
72 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT01164696 2010-08-24

A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

Bayer

Completed
30 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡